LLY vs MDT
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | LLY | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $1,216.95 | $82.39 | |
| Market cap as of 2026-07-10 | $1.15T | $104.8B | |
| P/E as of 2026-07-10 | 45.52 | 21.81 | MDT lower |
| PEG as of 2026-07-10 | 1.37 | 2.90 | LLY lower |
| Net margin as of 2026-07-10 | +35.0% | +13.2% | LLY higher |
| Gross margin as of 2026-07-10 | +82.8% | +65.3% | LLY higher |
| Operating margin as of 2026-07-10 | +43.6% | +17.8% | LLY higher |
| ROE as of 2026-07-10 | +101.3% | +9.8% | LLY higher |
| ROA as of 2026-07-10 | +22.7% | +5.2% | LLY higher |
| Debt / equity as of 2026-07-10 | 1.39 | 0.57 | MDT lower |
| Revenue growth (YoY) as of 2026-07-10 | +47.4% | +8.4% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +5.2% | LLY higher |
| Dividend yield as of 2026-07-10 | +0.6% | +3.5% | MDT higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.50 | 0.58 | |
| 1-year return as of 2026-07-09 close | +54.6% | -7.4% | LLY higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.